Therapeutic Delivery

Scope & Guideline

Elevating Pharmaceutical Science with Cutting-Edge Research

Introduction

Delve into the academic richness of Therapeutic Delivery with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN2041-5990
PublisherNewlands Press Ltd
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 2010 to 2024
AbbreviationTHER DELIV / Ther. Deliv.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address2 Albert Pl, London N3 1QB, UNITED KINGDOM

Aims and Scopes

The journal 'Therapeutic Delivery' focuses on advancing the field of drug delivery systems through innovative research and comprehensive reviews. The main aims and scopes encompass a variety of methodologies and applications that address the challenges in therapeutic delivery across multiple diseases.
  1. Nanotechnology in Drug Delivery:
    A significant emphasis on the utilization of nanotechnology to enhance drug delivery systems, including nanocarriers, nanomedicines, and nanoemulsions, aimed at improving bioavailability and targeting specific sites in the body.
  2. Targeted and Controlled Release Systems:
    Research dedicated to developing targeted delivery mechanisms that allow for controlled release of therapeutics, thereby maximizing efficacy while minimizing side effects, particularly in cancer and chronic diseases.
  3. Innovative Formulation Strategies:
    Exploration of novel formulation techniques, such as microemulsions, liposomes, and hydrogels, to optimize the delivery of pharmaceuticals, ensuring stability and improved therapeutic outcomes.
  4. Therapeutics for Diverse Diseases:
    A broad scope that includes the development of drug delivery systems for various diseases, including cancer, neurodegenerative disorders, infectious diseases, and metabolic conditions.
  5. Quality by Design (QbD) Approaches:
    Incorporating QbD principles into the formulation and development of drug delivery systems to ensure consistent quality and performance of therapeutics.
Recent publications in 'Therapeutic Delivery' show a clear trajectory towards emerging themes and trending topics that reflect the current needs and advancements in the field of drug delivery. These themes are gaining traction and are indicative of future research directions.
  1. Gene Therapy and RNA Delivery Systems:
    An increasing focus on the development of delivery systems for nucleic acids, including siRNA and gene therapy approaches, suggests a trend towards leveraging genetic interventions in treatment protocols.
  2. Personalized Medicine Applications:
    Research is trending towards personalized drug delivery systems tailored to individual patient profiles, particularly in oncology, which enhances therapeutic efficacy and minimizes adverse effects.
  3. Sustainable and Green Formulations:
    Emerging interest in sustainable drug delivery methods, including biodegradable materials and eco-friendly formulations, aligns with global trends towards environmental responsibility in pharmaceutical development.
  4. Advanced Targeting Techniques:
    Innovations in targeting mechanisms, such as the use of aptamers and antibodies for specific cellular targeting, are increasingly prevalent, showcasing a shift towards precision medicine.
  5. Combination Therapies and Multi-Drug Delivery Systems:
    There is a rising trend in research focused on combination therapies utilizing multi-drug delivery systems, particularly for complex diseases like cancer, to enhance treatment outcomes.

Declining or Waning

As the field of drug delivery evolves, certain themes within 'Therapeutic Delivery' appear to be diminishing in frequency or prominence. This section highlights these waning areas, reflecting the journal's shifting focus.
  1. Traditional Drug Delivery Methods:
    There is a noticeable decline in publications focused on conventional drug delivery methods, as the journal increasingly highlights advanced technologies and innovative formulations that offer enhanced efficacy.
  2. Non-targeted Systems:
    Papers discussing non-targeted drug delivery systems are less frequent, indicating a shift towards more sophisticated, targeted approaches that improve therapeutic outcomes.
  3. General Reviews without Novel Insights:
    There is a waning interest in general review articles that do not present new data or insights, with a preference now for studies that provide innovative methodologies or significant advancements in the field.

Similar Journals

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Exploring the Nexus of Science and Drug Development
Publisher: MARY ANN LIEBERT, INCISSN: 1540-658XFrequency: 8 issues/year

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.

ADVANCED DRUG DELIVERY REVIEWS

Transforming Pharmaceutical Frontiers.
Publisher: ELSEVIERISSN: 0169-409XFrequency: 12 issues/year

ADVANCED DRUG DELIVERY REVIEWS, published by ELSEVIER, is a leading journal in the field of pharmaceutical sciences, particularly acclaimed for its contributions to the disciplines of pharmacology, toxicology, and pharmaceutics. With an impressive 2023 Scopus rank of #1 out of 183 in its category, this journal is situated in the Q1 quartile, reflecting its high impact and the relevance of its published research. Since its inception in 1987, it has continually focused on the latest advancements in drug delivery systems, making it an indispensable resource for researchers, professionals, and students interested in the innovative developments that shape the pharmaceutical landscape. The journal aims to publish comprehensive and authoritative reviews that foster a deeper understanding of drug delivery mechanisms, technologies, and their clinical applications. Although it operates under a subscription model, the value it provides through rigorous peer-reviewed content ensures it remains an essential tool for anyone seeking to enhance their knowledge in this rapidly evolving field.

Expert Opinion on Drug Delivery

Navigating the Future of Drug Delivery Through Expert Analysis
Publisher: TAYLOR & FRANCIS LTDISSN: 1742-5247Frequency: 12 issues/year

Expert Opinion on Drug Delivery is a leading journal in the field of pharmaceutical science, published by Taylor & Francis Ltd. With an impressive impact factor and a prestigious Q1 ranking in 2023, it stands out as a vital resource for researchers, professionals, and students dedicated to advancing drug delivery technologies. Established in 2004, the journal has consistently provided a platform for critical insights and expert analyses, bridging the gap between innovation and application in drug delivery systems. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures the dissemination of high-quality research that significantly contributes to the fields of pharmacology, toxicology, and pharmaceutics. With its robust ranking of 13th out of 183 in Scopus, the journal continues to foster discourse and collaboration among experts, thereby enhancing the advancement of therapeutic options and improving patient outcomes.

Asian Journal of Pharmaceutical Sciences

Empowering discoveries in the realm of pharmaceutical sciences.
Publisher: SHENYANG PHARMACEUTICAL UNIVISSN: 1818-0876Frequency: 6 issues/year

Asian Journal of Pharmaceutical Sciences is a prestigious open-access journal published by Shenyang Pharmaceutical University, dedicated to advancing research and developments in the field of pharmaceutical sciences. Since its inception in 2009, the journal has successfully converged a wealth of knowledge and innovation, demonstrating an impressive track record with its open access model adopted in 2013, ensuring global dissemination of crucial research findings. With an outstanding impact factor and consistently ranked in the Q1 category for both Pharmaceutical Science and Pharmacology in 2023, it ranks among the top journals in its field, as evidenced by its impressive Scopus rankings—4th out of 183 in Pharmaceutical Science and 10th out of 313 in Pharmacology, showcasing its high relevance and credibility (98th and 96th percentiles respectively). Researchers, professionals, and students can access a diverse array of articles that encompass groundbreaking studies, reviews, and reports, solidifying the journal's position as a vital resource for anyone engaged in pharmaceutical research. With its commitment to quality and accessibility, Asian Journal of Pharmaceutical Sciences plays an essential role in fostering innovation and collaboration within the global scientific community.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Connecting Researchers to the Latest in Medicinal Chemistry.
Publisher: ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIERISSN: 0223-5234Frequency: 18 issues/year

European Journal of Medicinal Chemistry, a premier publication by Elsevier France-Editions Scientifiques Médicales Elsevier, has been at the forefront of advancing medicinal chemistry since its inception in 1974. With an impressive impact factor and ranking in the Q1 quartile across multiple categories including Drug Discovery, Medicine (miscellaneous), Organic Chemistry, and Pharmacology, this journal delivers cutting-edge research and reviews that are vital for researchers and professionals in the field. The journal’s scope encompasses the design, synthesis, and evaluation of biological activity of bioactive compounds, making it a critical resource for those looking to innovate in drug development and therapeutic strategies. Although currently not open access, subscribers can benefit from its diverse range of high-quality articles, ensuring the dissemination of knowledge in the ever-evolving landscape of medicinal chemistry. The European Journal of Medicinal Chemistry continues to play a pivotal role in shaping the future of pharmacological research and its application, thus appealing to an audience dedicated to making impactful scientific contributions.

International Journal of Pharmaceutics

Pioneering innovations in drug formulation and delivery.
Publisher: ELSEVIERISSN: 0378-5173Frequency: 21 issues/year

The International Journal of Pharmaceutics, a prestigious publication from ELSEVIER, stands at the forefront of the pharmaceutical science field, exemplified by its impressive ranking of #15 out of 183 in Pharmacology, Toxicology, and Pharmaceutics, placing it in the 92nd percentile. Established in 1978, this journal has continuously provided a platform for researchers, professionals, and students to share groundbreaking discoveries and innovations in drug formulation, delivery systems, and pharmacokinetics. With a Q1 ranking in the 2023 category of Pharmaceutical Science, it underscores its significance in disseminating high-quality research that shapes clinical practices and enhances therapeutic outcomes. While the journal does not currently offer open access options, it remains accessible to subscribers through its publication based in Amsterdam, Netherlands, ensuring a broad reach within the scientific community. As it converges towards a vibrant future, the International Journal of Pharmaceutics continues to be an essential resource for anyone dedicated to advancing the field of pharmacy and drug development.

JOURNAL OF CONTROLLED RELEASE

Shaping the evolution of controlled release methodologies.
Publisher: ELSEVIERISSN: 0168-3659Frequency: 24 issues/year

JOURNAL OF CONTROLLED RELEASE is a premier academic journal published by Elsevier that is dedicated to advancing the field of pharmaceutical science with a focus on drug delivery systems. Established in 1984, the journal has consistently served as a vital platform for disseminating high-quality research and innovative ideas in the area of controlled release technologies. With an impressive impact factor and ranking in the Q1 category of Pharmaceutical Science, it ranks #3 out of 183 in Scopus for its field, reflecting its influence and significance within the academic community, as noted by its percentile of 98th. The journal encompasses a wide range of topics, including polymer science, pharmacokinetics, and bioengineering, ensuring it remains at the forefront of pharmaceutical advancements. While currently not offering open access options, the journal serves a diverse audience of researchers, professionals, and students who are eager to push the boundaries of knowledge in drug delivery and therapeutics. For those looking to make impactful contributions in this dynamic field, JOURNAL OF CONTROLLED RELEASE is an essential resource for both foundational studies and cutting-edge research findings.

Journal of Pharmaceutical Innovation

Catalyzing Collaboration in Drug Discovery
Publisher: SPRINGERISSN: 1872-5120Frequency: 4 issues/year

The Journal of Pharmaceutical Innovation, published by SPRINGER, serves as a vital resource in the fields of Pharmaceutical Science and Drug Discovery. With an ISSN of 1872-5120 and an E-ISSN of 1939-8042, this journal has been disseminating significant research findings since its inception in 2006. It is recognized for its rigorous peer-review process, maintaining a respectable ranking of Q2 in Pharmaceutical Science and Q3 in Drug Discovery as of 2023. Researchers and practitioners benefit from the journal's diverse scope, which encompasses innovative methodologies and advancements in pharmaceuticals, thereby fostering knowledge and collaboration within the scientific community. Although it does not offer Open Access options, the journal is accessible through institutional subscriptions and libraries, ensuring that critical insights in drug development and pharmacology reach a broad audience. The geographical presence of the journal in the United States underscores its influence in shaping the pharmaceutical landscape on a global scale.

Advanced Pharmaceutical Bulletin

Catalyzing Collaboration in Cutting-edge Pharmaceutical Research
Publisher: TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICESISSN: 2228-5881Frequency: 2 issues/year

Advanced Pharmaceutical Bulletin, an esteemed journal published by Tabriz University of Medical Sciences & Health Services, serves as a pivotal platform for disseminating groundbreaking research in the field of pharmaceutical sciences. Since its inception in 2011, this open-access journal has dedicated itself to advancing knowledge in pharmacology, toxicology, and pharmaceutics, boasting an impressive Q1 ranking in miscellaneous categories and Q2 in pharmaceutical science as of 2023. The journal is noted for its rigorous peer-review process, ensuring that published work meets the highest standards of scientific inquiry. With notable rankings, including 7th out of 80 in general pharmacology and toxicology, it sits in the 91st percentile, highlighting its significance in the research community. Researchers and practitioners alike can access cutting-edge findings and innovative methodologies, promoting collaboration and knowledge within the scientific community. Based in Tabriz, Iran, the journal remains committed to fostering research excellence, making it an invaluable resource for scholars and professionals eager to contribute to the dynamic field of pharmaceuticals.

JOURNAL OF DRUG TARGETING

Pioneering advancements in drug targeting and delivery.
Publisher: TAYLOR & FRANCIS LTDISSN: 1061-186XFrequency: 10 issues/year

JOURNAL OF DRUG TARGETING, published by Taylor & Francis Ltd, is a premier academic journal dedicated to advancing the field of pharmaceutical sciences with a strong focus on drug delivery and targeting methodologies. With an impressive impact factor and recognized as a Q1 journal in the Pharmaceutical Science category, it ranks #23 out of 183 in Pharmacology, Toxicology and Pharmaceutics, placing it within the top 13% of journals in its field. The journal provides a platform for interdisciplinary research, showcasing innovative techniques and breakthrough findings that serve to improve therapeutic efficacy through precision targeting. Although it operates under a subscription model, researchers benefit from extensive access to pivotal studies spanning from 1986 to 2024. The JOURNAL OF DRUG TARGETING aims to foster collaboration among academics, professionals, and students, making it an essential resource for those seeking to leverage the latest advancements in drug development and delivery systems for improved healthcare outcomes.